Skip to main content

Table 2 Treatment-related adverse events

From: Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study

  Disease stage
ND (n = 1599) HD (n = 1408) PD (n = 336)
ADRs, n (%) SADRs, n (%) ADRs, n (%) SADRs, n (%) ADRs, n (%) SADRs, n (%)
Any 49 (3.06) 21 (1.31) 59 (4.19) 35 (2.48) 15 (4.46) 6 (1.78)
Number of cases that had ≥ 2 ADRs
 Hypertension 15 (0.93) 0 16 (1.13) 1 (0.07) 5 (1.48) 0
 Increased BP 1 (0.06) 0 4 (0.28) 0 1 (0.29) 0
 IDA 4 (0.25) 0 3 (0.21) 0 0 0
 Anemia 2 (0.12) 2 (0.12) 10 (0.71) 10 (0.71) 2 (0.59) 2 (0.59)
 Cerebral infarction 1 (0.06) 1 (0.06) 4 (0.28) 4 (0.28) 0 0
 Shunt occlusion 1 (0.06) 1 (0.06) 5 (0.35) 5 (0.35) 0 0
 Cerebral hemorrhage 0 0 2 (0.14) 2 (0.14) 0 0
 Subdural hematoma 2 (0.12) 2 (0.12) 0 0 0 0
 Diabetic nephropathy 2 (0.12) 2 (0.12) 0 0 0 0
 Increased Hb 2 (0.12) 0 0 0 0 0
 Decreased platelets 2 (0.12) 0 1 (0.07) 1 (0.07) 0 0
 Decreased appetite 0 0 2 (0.14) 2 (0.14) 0 0
  1. ADRs adverse drug reactions, BP blood pressure, Hb hemoglobin, HD hemodialysis, IDA iron deficiency anemia, ND not on dialysis, PD peritoneal dialysis, SADRs serious adverse drug reactions